Literature DB >> 10648030

Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.

K Russo1, S Hoch, C Dima, J Varga, M Teodorescu.   

Abstract

OBJECTIVE: To determine the disease sensitivity and specificity of testing for autoantibodies against 2 of the 3 main human centromere antigenic components, CENP-A and CENP-B (recombinant, expressed in baculovirus).
METHODS: ELISA with CENP-A and CENP-B antigens were used to test 45 sera showing a centromere pattern by immunofluorescence (IFA) and sera from 96 patients with systemic sclerosis (SSc), subdivided into diffuse (dSSc) and limited (lSSc) forms. For controls, the same tests were performed on sera from 100 patients with rheumatoid arthritis (RA), 100 with systemic lupus erythematosus (SLE), and 50 random blood donors. Sera from all the patients with SSc were also tested for the presence of anti-Scl70 antibody by ELISA (bovine antigen), and for pattern and titer by IFA (HEp-2 cells).
RESULTS: Of the 45 IFA positive sera, 93% were positive for anti-CENP-A and 91% for anti-CENP-B. There was a very good quantitative correlation between the antibody levels against these 2 centromere components (r = 0.597; p<0.001). Anti-CENP-A and B were found in 48% of patients with lSSc, and in 11% and 9%, respectively, of those with dSSc. The difference in the frequency of anti-CENP-A between the 2 patient groups was significant (chi-squared, p<0.001). Similar levels of anticentromere staining pattern by IFA were observed for these 2 groups. Anti-Scl70 was elevated in 8% of lSSc and 25% of dSSc patients; this difference was also significant (chi-squared, p = 0.02). Neither CENP-A nor CENP-B reacted with IgG from SSc patients containing anti-Scl70. The frequency of abnormal levels in patients with SLE and RA was, respectively, 11% and 3% for anti-CENP-A and 4% and 3% for anti-CENP-B. The reaction of IgG from SLE and RA patients with CENP-A was not inhibited by histone H3, i.e., it was not due to recognition of the histone-like domain in CENP-A. Thus, when 96 SSc patients were compared to 200 patients with RA and SLE, the disease specificity of anti-CENP-A and B was 93% and 96.5%, respectively.
CONCLUSION: In addition to IFA, ELISA tests for CENP-A and CENP-B yield results with similar sensitivity and specificity for the diagnosis of SSc. CENP-A and CENP-B are primarily associated with lSSc. In SSc the autoantibody response is directed simultaneously and with similar amplitude against these 2 components of the centromere structure, whereas in other autoimmune diseases the response is directed mainly against one of the 2 components.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648030

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.

Authors:  Chao-Jun Hu; Guang Song; Wei Huang; Guo-Zhen Liu; Chui-Wen Deng; Hai-Pan Zeng; Li Wang; Feng-Chun Zhang; Xuan Zhang; Jun Seop Jeong; Seth Blackshaw; Li-Zhi Jiang; Heng Zhu; Lin Wu; Yong-Zhe Li
Journal:  Mol Cell Proteomics       Date:  2012-05-30       Impact factor: 5.911

3.  Plasmonic substrates for multiplexed protein microarrays with femtomolar sensitivity and broad dynamic range.

Authors:  Scott M Tabakman; Lana Lau; Joshua T Robinson; Jordan Price; Sarah P Sherlock; Hailiang Wang; Bo Zhang; Zhuo Chen; Stephanie Tangsombatvisit; Justin A Jarrell; Paul J Utz; Hongjie Dai
Journal:  Nat Commun       Date:  2011-09-13       Impact factor: 14.919

Review 4.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

5.  New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays.

Authors:  Guang Song; Chaojun Hu; Heng Zhu; Li Wang; Fengchun Zhang; Yongzhe Li; Lin Wu
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

6.  Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies.

Authors:  Yasmin Akbarali; Jennifer Matousek-Ronck; Laura Hunt; Leslie Staudt; Morris Reichlin; Joel M Guthridge; Judith A James
Journal:  J Autoimmun       Date:  2007-01-08       Impact factor: 7.094

7.  CENPA a genomic marker for centromere activity and human diseases.

Authors:  Manuel M Valdivia; Khaoula Hamdouch; Manuela Ortiz; Antonio Astola
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

8.  Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody.

Authors:  Takashi Himoto; Seiji Nakai; Fumihiko Kinekawa; Hirohito Yoneyama; Akihiro Deguchi; Kazutaka Kurokochi; Tsutomu Masaki; Shoichi Senda; Reiji Haba; Seishiro Watanabe; Mikio Nishioka; Shigeki Kuriyama
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

9.  Clinical and serological evaluation of a novel CENP-A peptide based ELISA.

Authors:  Michael Mahler; Liesbeth Maes; Daniel Blockmans; Rene Westhovens; Xavier Bossuyt; Gabriela Riemekasten; Sandra Schneider; Falk Hiepe; Andreas Swart; Irmgard Gürtler; Karl Egerer; Margrit Fooke; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2010-05-20       Impact factor: 5.156

10.  Novel autoantigens immunogenic in COPD patients.

Authors:  Petra Leidinger; Andreas Keller; Sabrina Heisel; Nicole Ludwig; Stefanie Rheinheimer; Veronika Klein; Claudia Andres; Jürg Hamacher; Hanno Huwer; Bernhard Stephan; Ingo Stehle; Hans-Peter Lenhof; Eckart Meese
Journal:  Respir Res       Date:  2009-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.